High incidence of subclinical peripheral artery disease in people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
25
5
2022
medline:
28
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
Atherosclerosis is common in people with HIV (PWH). Peripheral artery disease (PAD) is the peripheral manifestation of atherosclerosis, but little is known about the incidence of PAD in PWH. Our objective was to determine the PAD incidence in PWH and to investigate potential risk factors. Prospective longitudinal study on PWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study cohort. We performed ankle-brachial index (ABI) measurements at study entry and at 2-year follow-up and included participants with normal ABI at study entry. We defined de novo PAD as ABI ≤0.9 at follow-up. Using Poisson regression adjusted for age, sex, and smoking, we investigated the role of traditional and HIV-related risk factors, including inflammatory markers. Of 844 PWH followed for a median duration of 2.3 years, 30 (3.6%) developed de novo PAD. All cases were subclinical. Diabetes (relative risk [RR] = 4.90 [95% confidence interval [CI]: 1.99-12.1]), current CD4 + cell count <350 cells/μl (2.66 [1.06-6.71]), longer duration of antiretroviral therapy (antiretroviral therapy [ART], 1.88 [1.06-3.33] per decade), and concentrations of high-sensitivity C-reactive protein (1.33 [1.08-1.63] per doubling) and interleukin-6 (1.38 [1.06-1.80] per doubling), were associated with de novo PAD. PWH had a high incidence of de novo subclinical PAD. Diabetes, low current CD4 + cell count, duration of ART, and inflammatory markers were associated with de novo PAD, indicating a possible role in PAD pathogenesis in PWH.
Identifiants
pubmed: 35608109
doi: 10.1097/QAD.0000000000003252
pii: 00002030-202208010-00004
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1355-1362Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management . Nat Rev Cardiol 2019; 16:745–759.
Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV systematic review and meta-analysis . Circulation 2018; 138:1100–1112.
Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis . Lancet 2013; 382:1329–1340.
Fowkes FGR, Aboyans V, Fowkes FJI, McDermott MM, Sampson UKA, Criqui MH. Peripheral artery disease: epidemiology and global perspectives . Nat Rev Cardiol 2016; 14:156–170.
Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis . J Am Med Assoc 2008; 300:197–208.
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease . Circ Res 2015; 116:1509–1526.
Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association . Circulation 2012; 126:2890–2909.
Knudsen AD, Gelpi M, Afzal S, Ronit A, Roen A, Mocroft A, et al. Prevalence of peripheral artery disease is higher in persons living with HIV compared with uninfected controls . J Acquir Immune Defic Syndr 2018; 79:381–385.
Schouten J, Wit FW, Stolte IG, Kootstra NA, Van Der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study . Clin Infect Dis 2014; 59:1787–1797.
Gupta N, Bajaj S, Shah P, Parikh R, Gupta I, Dhillon W, et al. The prevalence of peripheral arterial disease in HIV patients . J Vasc Med Surg 2013; 1:1000118.
Palacios R, Alonso I, Hidalgo A, Aguilar I, Sánchez MA, Valdivielso P, et al. Peripheral arterial disease in HIV patients older than 50 years of age . AIDS Res Hum Retroviruses 2008; 24:1043–1046.
Cedarbaum E, Ma Y, Scherzer R, Price JC, Adimora AA, Bamman M, et al. Contributions of HIV, hepatitis C virus, and traditional vascular risk factors to peripheral artery disease in women . AIDS 2019; 33:2025–2033.
Aurpibul L, Sugandhavesa P, Srithanaviboonchai K, Sitthi W, Tangmunkongvorakul A, Chariyalertsak C, et al. Peripheral artery disease in HIV-infected older adults on antiretroviral treatment in Thailand . HIV Med 2019; 20:54–59.
Sharma A, Holman S, Pitts R, Minkoff HL, DeHovitz JA, Lazar J. Peripheral arterial disease in HIV-infected and uninfected women . HIV Med 2007; 8:555–560.
Tan BK, Chalouni M, Ceron DS, Cinaud A, Esterle L, Loko MA, et al. Atherosclerotic cardiovascular events in patients infected with human immunodeficiency virus and hepatitis C virus . Clin Infect Dis 2021; 72:e215–e223.
Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database . J Am Hear Assoc 2019; 8:e012241.
Masiá M, Padilla S, García JA, García-Abellán J, Fernández M, Bernardino I, et al. Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004–2015 . PLoS One 2019; 14:e0215507.
Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz MB, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease . Circulation 2018; 138:255–265.
Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons . AIDS 2011; 25:1289–1298.
Ronit A, Haissman J, Kirkegaard-Klitbo DM, Kristensen TS, Lebech AM, Benfield T, et al. Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, noninterventional assessment of non-AIDS comorbidity in HIV infection in Denmark . BMC Infect Dis 2016; 16:713.
Center for Disease Control and Prevention (CDC) Revised surveillance case definition for HIV infection − United States, 2014 . MMWR Recomm Rep 2014; 63:1–10.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines . Hypertension 2020; 75:1334–1357.
American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021 . Diabetes Care 2021; 44: (Suppl 1): S15–S33.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCN: a guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines . Circulation 2019; 139:e1082–e1143.
International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome. Available at: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html [Accessed 12 March 2022].
World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO consultation . World Health Organ Tech Rep Ser 2000; 894:1–253.
R Core Development Team. R: a language and environment for statistical computing. Available at: http://www.r-project.org [Accessed 16 January 2022].
Boyes R. Forester: an R package for creating publication-ready forest plots. Available at: https://github.com/rdboyes/forester [Accessed 16 January 2022].
Hooi JD, Kester ADM, Stoffers HEJH, Overdijk MM, van Ree JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study . Am J Epidemiol 2001; 153:666–672.
Rosenson RS, Hubbard D, Monda KL, Reading SR, Chen L, Dluzniewski PJ, et al. Excess risk for atherosclerotic cardiovascular outcomes among US adults with HIV in the current era . J Am Hear Assoc 2020; 9:e013744.
Cedarbaum ER, Ma Y, Adimora AA, Bamman M, Cohen MH, Fischl MA, et al. Peripheral artery disease and physical function in women with and without HIV . AIDS 2022; 36:347–354.
Rb-Silva R, Goios A, Kelly C, Teixeira P, João C, Horta A, et al. Definition of immunological nonresponse to antiretroviral therapy: a systematic review . J Acquir Immune Defic Syndr 2019; 82:452–461.
Friis-Møller N, Sabin C, Weber R, d’Arminio Monforte A, El-Sadr W, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction . N Engl J Med 2003; 349:1993–2003.
Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection . N Engl J Med 2015; 373:795–807.
Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. D:A:D Study Group Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration . Lancet 2008; 371:1417–1426.
Kovari H, Calmy A, Doco-Lecompte T, Nkoulou R, Marzel A, Weber R, et al. Antiretroviral drugs associated with subclinical coronary artery disease in the Swiss human immunodeficiency virus cohort study . Clin Infect Dis 2020; 70:884–889.
Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study . J Infect Dis 2010; 201:318–330.
Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care . AIDS 2011; 25:185–195.
De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients . Diabetes Care 2008; 31:9.
Shaked I, Hanna DB, Gleißner C, Marsh B, Plants J, Tracy D, et al. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection . Arterioscler Thromb Vasc Biol 2014; 34:1085–1092.
Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, et al. A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease . Rev Med Virol 2018; 28:e1953.
Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy . PLoS One 2016; 11:e0155100.
Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy . AIDS 2016; 30:2065–2074.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection . PLoS Med 2008; 5:e203.
Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment . J Infect Dis 2014; 210:1248–1259.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study . Circulation 2005; 112:976–983.
Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure . Cytokine 2015; 74:62–68.
Reiner AP, Lange EM, Jenny NS, Chaves PHM, Ellis J, Li J, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults . Arterioscler Thromb Vasc Biol 2013; 33:158–164.
Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis . Atherosclerosis 2006; 184:342–347.